Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sunnybrook Health Sciences Centre
Age
55–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged \>55 years
Meet Diagnostic and Statistical Manual - IV (DSM-IV) criteria for primary degenerative dementia
Meet National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD of at least one year's duration
Score ≤15 on the Mini-Mental State Examination (MMSE) (severe dementia)
Receiving donepezil (5 or 10 mg), galantamine (8, 16 or 24 mg) or rivastigmine (3, 4.5 or 6 mg oral) for at least 2 years, with a stable dose for at least 3 months prior to study entry
Patients with a current order for any regularly administered psychotropic (e.g. selective serotonin reuptake inhibitor (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), trazodone, atypical or typical antipsychotics) must have been on a stable dose for at least 1 month prior to study entry
You may not be if
Patients with the following conditions will be excluded:
Dementia due to any etiology other than Alzheimer's Disease (AD)
Significant difficulty ingesting oral medications
Current evidence of any uncontrolled medical illness that would interfere with the subject's participation in the study
